S. Windecker

Discipline

Psychologie (5) Economies et finances (2)

Type de document

Articles (31) Recensions (2)

Co-auteur

Date

Source

Mot-clé

Patients (27) Patients (27) Human beings (23) Treatment (16) Ci (Chinese poetry) (16) Syndromes (15) risque (14) Risk (14) Myocardial infarction (14) Death (13) Death (13) Older people (13) cohorte (13) mort (13) procès (11) Rates (11) Year (11) Rates (11) âge (10) Design (10) Age (10) Design (10) Age (10) mortalité (9) danger (9) Mortality (9) Mortality (9) association (8) analyse (8) Swiss (8)

Documents écrit par S. Windecker (31) | parle de S. Windecker (0)

Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
J.D. Häner et al.
Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome.
L. Clement et al. (1 janv. 2023)
Smoking cessation and depression after acute coronary syndrome.
K. Krasieva et al.
Long-term effects of systematic smoking cessation counselling during acute coronary syndrome, a multicentre before-after study.
L. Gilgien-Dénéréaz et al. (18 juil. 2022)
Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial.
J.F. Iglesias et al.
Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland.
I. Worni-Schudel et al.
Cysteine-Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute Coronary Events) 2.0 Risk Score in Patients With Acute Coronary Syndromes.
R. Klingenberg et al. (19 oct. 2021)
Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: A meta-analysis of individual patient data from 5 randomized trials.
T. Pilgrim et al.
Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI: Final 2-Year Outcomes of the BIOSTEMI Trial.
T. Pilgrim et al. (22 mars 2021)
Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events.
R. Klingenberg et al.
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.
S. Barco et al. (9 sept. 2020)
The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial.
R. Wang et al.
Optimal Timing of Invasive Coronary Angiography following NSTEMI.
T. Mahendiran et al. (2020)
Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61.
P. Winzap et al. (31 oct. 2019)
Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes.
N. Vuilleumier et al. (9 juil. 2019)
Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention.
D. Carballo et al. (2019)
Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction.
K.C. Koskinas et al. (13 avr. 2018)
Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome.
S. Canivell et al. (2018)
Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.
F. Mahfoud et al. (21 nov. 2017)
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
B. Gencer et al. (9 nov. 2017)
Repositionable Versus Balloon-Expandable Devices for Transcatheter Aortic Valve Implantation in Patients With Aortic Stenosis.
T. Pilgrim et al. (17 nov. 2016)
Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before-after study with parallel group comparisons.
R. Auer et al. (20 sept. 2016)
Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.
R. Laaksonen et al. (1 juil. 2016)
Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
R. Zbinden et al. (2016)
Health utility indexes in patients with acute coronary syndromes.
B. Gencer et al. (2016)

next